W2W4 at SITC23 - 10 emerging areas to pay attention to in IO
From CAR-T cells to protein degradation
Early-stage agents in development for multiple myeloma - hit or miss?
Encouraging new developments in the CAR-NK niche
What do three phase 1 and one phase 2 trials tell us about future development?
How can we overcome immune escape in relation to TIGIT therapies?
Ten emerging development areas to watch out for in oncology during 2023
10 early stage IO biotechs to watch out for
6 abstracts to watch out for on how to overcome immune escape
Interview with Dr Vipin Suri, CSO Catamaran Bio about the science behind their CAR-NK cell therapy.
First in a mini-series featuring some of the companies that presented CAR-NK cell data at AACR22
A look at early stage CAR-T cell therapies in development
Can NK cells help checkpoint blockade work more effectively?
Looking beyond the hype from a broader perspective
Highlights from Day 1 of CART22, part 1
A look at some combination IO strategies in early clinical development to watch out for
Novel approaches to fine tuning CAR-T cell therapies are hitting the clinic
Update on the various runners and riders in the TIGIT niche
A look at the sheer breadth and depth of bispecific approaches from a myriad of different biotechs
A deep dive into the phase 2 COAST study, along with some expert anecdotes
13 ways in which CAR based or gene therapies can improve on current approaches to cell therapies
13 talks at AACR21 caught our attention - which ones intrigued or dismayed - and why?
What's hot in early preclinical development to watch out for?
Noteworthy AACR21 on-demand presentations.
A critical look at the early stage BMS oncology pipeline
Commentary on engineered NK cells, including CAR-NK and memory-like NK cells
Expert commentary on new data relating to NK cell therapies - are they ready for prime time yet or not?
Commentary on Saturday at ASH20
A new emerging IO target of interest caught out attention, now what?
Can we make NK cells work harder with gene editing? It looks as though this will be a feasible strategy to pursue...
Will CAR-NK cells follow CAR-T cell therapies and hit prime time?
Can innovative our ability to reinvigorate stalled CAR T cells affected by immune escape from CD19 loss or downregulation of BCMA?
Highlights (and lowlights) from the second day of the JPM Healthcare conference in San Francisco
What can we learn from the recent data presented on Affimed's innate bispecific platform? A candid conversation with CEO, Dr Adi Hoess
Round-up and analysis of key lymphoma data at iCML 2019
A review of 7 different targets and 18 different compounds in the maturing and highly competitive bispecific niche.
Will NK cell engagers have a positive impact on checkpoint therapy and other adaptive immunotherapies?
An in-depth look at the French biotech company Innate Pharma and where they are now two years on from our last look at their IO pipeline.
A look at what Gamida Cell, an up and coming cellular and innate immunotherapy company are up to...
A look at targeting NK cells with immune agonists, cytokines and adoptive cell therapies
The Mav's key oral abstracts to follow at #ASH17 -- warning this list includes quirky selections!
Can we address inhibitory factors that dampen NK cells to enhance the anti-cancer effect on tumours?
Update on Nektar Therapeutics IO portfolio and a look at their burgeoning autoimmune disorder pipeline
New research shows potential of cell therapy with allogeneic memory-like natural killer NK cells in AML.
Interview with Innate Pharma CEO Dr Hervé Brailly on clinical trial readouts expected and his vision for company
Professor Eric Vivier is Director of the Centre d’Immunologie de Marseille-Luminy and a co-founder of Innate Pharma and the Marseille Immunopôle. He is a leading researcher in the field of innate immunity.
Interview at BMT Tandem 2016 about a novel cell therapy that could compete with or replace CAR T cell therapy
Immuno-oncology is a hot topic at the moment and many new targets are emerging that may be useful in combination. This post discusses Innate Pharma's anti-KIR program in hematologic malignancies.
